HTS and hit finding in academia - from chemical genomics to drug discovery

Julie A. Frearson, Iain T. Collie

    Research output: Contribution to journalArticlepeer-review

    63 Citations (Scopus)
    5 Downloads (Pure)

    Abstract

    The liaison between academia and the pharmaceutical industry was originally served primarily through the scientific literature and limited, specific industry-academia partnerships. Some of these partnerships have resulted in drugs on the market, such as Vorinostat (Memorial Sloan-Kettering Cancer Centre and Merck) and Tenofovir (University of Leuven; Institute of Organic Chemistry and Biochemistry, Czech Republic; and GlaxoSmithKline), but the timescales from concept to clinic have, in most cases, taken many decades. We now find ourselves in a world in which the edges between these sectors are more blurred and the establishment and acceptance of high-throughput screening alongside the wider concept of 'hit discovery' in academia provides one of the key platforms required to enable this sector to contribute directly to addressing unmet medical need.
    Original languageEnglish
    Pages (from-to)1150-1158
    Number of pages9
    JournalDrug Discovery Today
    Volume14
    Issue number23-24
    DOIs
    Publication statusPublished - Dec 2009

    Fingerprint Dive into the research topics of 'HTS and hit finding in academia - from chemical genomics to drug discovery'. Together they form a unique fingerprint.

    Cite this